Concerns about the COVID-19 shots have increased after a report that drug maker Moderna failed to inform the U.S. government ...

While the headline numbers don't inspire much confidence, Moderna is a stock that deserves a closer look. The company still ...

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.

including an extensive pipeline of therapeutics in clinical trials that could be the booster shot the stock needs to generate a rebound. It's been more than four years since Moderna rose to ...

Ward said it would be good to see data from studies of other variant vaccine boosters to compare to the Moderna combination. Expert advisors "must already be thinking about the population at risk ...

Hospitalizations and general "syndromic" cases were at 10+ statewide for the week. The number of reported COVID cases ...

The FDA has authorised booster shots with Moderna and Johnson & Johnson’s COVID-19 vaccines, a month after giving the go-ahead to a third-dose of Pfizer/BioNTech’s shot. It has also authorised ...

Jared Holz, Mizuho Healthcare Sector strategist, joins 'Closing Bell Overtime' to talk Moderna and Novo Nordisk.

Hence, researchers recommended that people who received it get a second booster dose with an mRNA vaccine such as Moderna and Pfizer. According to the published results, there were 129 coronavirus ...